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Dysregulated mitochondrial metabolism during he-
patic insulin resistance may contribute to patho-
physiologies ranging from elevated glucose pro-
duction to hepatocellular oxidative stress and
inflammation. Given that obesity impairs insulin ac-
tion but paradoxically activates mTORC1, we tested
whether insulin action andmammalian target of rapa-
mycin complex 1 (mTORC1) contribute to altered
in vivo hepatic mitochondrial metabolism. Loss of
hepatic insulin action for 2 weeks caused increased
gluconeogenesis, mitochondrial anaplerosis, tricar-
boxylic acid (TCA) cycle oxidation, and ketogenesis.
However, activation of mTORC1, induced by the loss
of hepatic Tsc1, suppressed these fluxes. Only
glycogen synthesis was impaired by both loss of in-
sulin receptor and mTORC1 activation. Mice with a
double knockout of the insulin receptor and Tsc1
had larger livers, hyperglycemia, severely impaired
glycogen storage, and suppressed ketogenesis, as
compared to those with loss of the liver insulin recep-
tor alone. Thus, activation of hepatic mTORC1 op-
poses the catabolic effects of impaired insulin action
under some nutritional states.INTRODUCTION
Hepatic insulin resistance is a key factor in many pathophysiol-
ogies of obesity, including diabetes and nonalcoholic fatty liver
disease (NAFLD). Defects in hepatic insulin signaling contribute
to poor glycemia by causing inadequate phosphorylation of
Foxo transcription factors that regulate gluconeogenesis and
by ineffectively modulating the phosphorylation of glycogen syn-
thase and glycogen phosphorylase (Lin and Accili, 2011). Meta-
bolic pathways that promote liver damage are also initiated by508 Cell Reports 16, 508–519, July 12, 2016 ª 2016 The Author(s).
This is an open access article under the CC BY-NC-ND license (http://loss of the insulin signaling, perhaps through effects on oxidative
metabolism (Haas et al., 2012) and oxidative damage (Michael
et al., 2000). Activation of oxidative metabolism in the liver of
obese humans (Iozzo et al., 2010; Sunny et al., 2011) suggests
a similar mechanism in NAFLD subjects. Inasmuch as inhibiting
pathways associated with the tricarboxylic acid (TCA) cycle pro-
tects against hepatic oxidative stress and inflammation in mice
(Satapati et al., 2015), oxidative metabolism appears to play a
critical role in the progression of NAFLD.
Chronic exposure to obesity eventually causes defects in he-
patic mitochondrial function (Mantena et al., 2009; Rector et al.,
2010; Thyfault et al., 2009), but some aspects of mitochondrial
metabolism may be altered prior to damage in response to
disruptions in insulin signaling. For example, despite insulin
resistance, insulin signaling over-activates hepatic lipogenesis
(Shimomura et al., 2000), a pathway normally antithetic to fat
oxidation. This ‘‘selective insulin resistance’’ occurs with the
paradoxical activation of signaling proteins downstream of the
insulin receptor. Specifically, mammalian target of rapamycin
complex 1 (mTORC1), a serine-threonine protein kinase with
broad roles in cell growth, replication, survival, aging, and meta-
bolism (Howell et al., 2013; Zoncu et al., 2011), lies downstream
of the insulin receptor and is required for elevated lipogenesis
during insulin resistance (Li et al., 2010). Importantly, mTORC1
target proteinsmay also act to suppress the expression of gluco-
neogenic (Lustig et al., 2011) and ketogenic genes in liver
(Sengupta et al., 2010). A key challenge for understanding the
molecular metabolism of insulin resistance is to determine how
downstream signaling nodes, like mTORC1, function to regulate
metabolic flux, particularly in mitochondria.
To test the hypothesis that hepatic mitochondrial metabolism
is altered by signaling components of insulin resistance, we
studied loss of insulin action and activation of mTORC1. Stable
isotope tracers were used to evaluate in vivo metabolic flux in
mice that were either fed chow or an 8-week high-fat diet
(HFD) after an acute (2-week) loss of the insulin receptor and/or
constitutive activation of mTORC1 by loss of Tsc1 (Kwiatkowski
et al., 2002). We report that loss of insulin action stimulated he-
patic TCA cycle metabolism and fat oxidation, similar to ourcreativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Characteristics of Mice Fed a Chow Diet with Short-Term
Hepatic Tsc1 or Insrb Removal
Mice on a chow diet (n = 4–7) were fed ad libitum or overnight (17 hr) fasted
prior to tracer infusions.
(A and B) Western blot analyses for Insrb (A) and Tsc1 (B) proteins in liver
lysates from animals sacrificed 14 days after Ad-Cre injection.
(C and D) Blood glucose concentration in InsrLKO (C) and Tsc1LKO (D) mice.
(E and F) Plasma insulin concentration in InsrLKO (E) and Tsc1LKO (F) mice.
(G and H) Endogenous glucose production measured by [3,4-13C]glucose
turnover in InsrLKO (G) and Tsc1LKO (H) mice.
(I and J) qRT-PCR analysis of genes related to glucosemetabolism in InsrLKO (I)
and Tsc1LKO (J) liver.
All parameters except blood glucose were analyzed after the end of infusion,
which required an additional 4-hr fast. Data are expressed as the mean and
SE, with significant differences determined by unpaired two-tailed Student’s
t test assuming equal variances and identified as *p < 0.05.previous findings in fasted mice after 16 weeks of an HFD (Sata-
pati et al., 2012). In contrast, a shorter (8-week) HFD suppressed
TCA cycle metabolism in fed mice, resulting in a blunted fed-to-
fasted increment in the flux. This effect was recapitulated by
mTORC1 activation. Glycogen metabolism was impaired by
both the loss of insulin receptor and activation of mTORC1. Acti-
vation of mTORC1 in insulin receptor knockout (KO) liver further
provoked hyperglycemia, worsened glycogen storage, and sup-
pressed fasting ketosis. Hence, loss of insulin action excited
mitochondrial metabolism, but mTORC1 activation suppressed
mitochondrial metabolism, and, together, they caused hypergly-
cemia with impaired hepatic fat oxidation, a combination
observed in severe diabetic models.
RESULTS
Short-Term Liver-Specific Tsc1 and Insrb Deletion Have
Opposite Effects on Hepatic Gluconeogenesis in Mice
To study the heterogeneous metabolic effects of loss of insulin
action and constitutive mTORC1 activation, we examined mice
with conditional loss of hepatic Insrb or Tsc1 for glucose homeo-
stasis (Figure 1). Liver-specific removal was mediated by Ad-Cre
(adenovirus coding for Cre recombinase) recombination of
floxed alleles in adult Tsc1F/F (TscLKO) and InsrbF/F (InsrLKO)
mice 2 weeks prior to experiments to minimize adaptive effects
due to long-term hepatic inactivation of Tsc1 (Kwiatkowski
et al., 2002) or Insrb (Michael et al., 2000). Ad-Cre treatment
led to 90% Tsc1 and Insrb knockdown (Figures 1A and 1B).
To account for the effect of Cre recombinase expression and
adenovirus infection, all control mice were injected with Ad-Cre.
Themetabolic effects of Insrb loss or mTORC1 gain of function
were first examined in mice fed a chow diet after an 4-hr (fed/
postabsorptive) or 24-hr (fasted) fast. Both genotypes had
normal plasma glucose concentrations in the fed and fasted
states (Figures 1C and D). However, insulin concentration was
significantly increased in the InsrLKO mice (Figure 1E) but not
the TscLKO mice (Figure 1F). To clarify whether 2 weeks of inac-
tivation of the insulin receptor or activation of mTORC1 is suffi-
cient to alter glucose homeostasis, we performed tracer studies
of endogenous glucose production (EGP). Glucose production
was significantly reduced in fasted mice compared to fed
mice, but neither loss of hepatic insulin receptor (Figure 1G)
nor activation of mTORC1 (Figure 1H) altered EGP. DespiteCell Reports 16, 508–519, July 12, 2016 509
Figure 2. Hepatocellular Gluconeogenesis
Is Induced by Loss of Insulin Action and
Suppressed by mTORC1 Activation
Mice on a chow diet (n = 4–7) were fed ad libitum or
overnight (17 hr) fasted.
(A and B) Liver:body weight in InsrLKO (A) and
Tsc1LKO (B) mice.
(C and D) Total liver protein content in InsrLKO (C)
and Tsc1LKO (D) mice.
(E–G) Since liver size was dramatically altered by
loss of Insr and Tsc1, gluconeogenic (GNG) flux in
InsrLKO (E) and Tsc1LKO (F) mice was measured
by 2H incorporation into plasma glucose H2 and
H5, and expressed in mmol , min1 , g liver
protein1. (G) Liver:body weight during a 24-hr fast
in Tsc1LKO mice.
All parameters were analyzed after the end of the
infusion, which required an additional 4-hr fast.
Data are expressed as the mean and SE, with
significant differences determined by unpaired
two-tailed Student’s t test assuming equal vari-
ances and identified as *p < 0.05.normal rates of glucose production, liver mRNA levels of several
enzymes of glucose metabolism were altered. Pck1 expression
(cytosolic phosphoenolpyruvate carboxykinase) was increased,
and Gck (glucokinase) was decreased in the liver of InsrLKOmice
(Figure 1I). These genes were expressed at relatively normal or
reduced expression in Tsc1LKO mice on a chow diet (Figure 1J)
or an HFD.
Since the insulin signaling pathway partially mediates growth,
we examined whether liver size was altered in InsrLKO or Tsc1LKO
mice (Figure 2). The liver:body ratio was decreased by 35% after
the loss of insulin receptor (Figure 2A) but increased by 35%after
mTORC1 activation (Figure 2B). The change in liver mass (Tables
S1 and S2) corresponded to a similar decrease in protein content
in InsrLKO liver (Figure 2C) and increased protein content in
Tsc1LKO liver (Figure 2D). Thus, although total glucose produc-
tion was normal in both models (Figure 1E), it was supported
by less liver mass in InsrLKOmice and more liver mass in Tsc1LKO
mice.
Deuterated water was administered, and 2H enrichments were
examined in plasma glucose (Table S3) to determine the relative
sources of hepatic glucose production (Table S4). Total gluco-
neogenesis relative to liver protein was dramatically elevated in
the fed and fasted states of InsrLKO mice on a chow diet (Fig-
ure 2E). In contrast, mTORC1 activation, due to loss of Tsc1,
caused a reduction of gluconeogenesis in chow-fed mice (Fig-
ure 2F). Since mTORC1 activation is associated with insulin
resistance, we fed Tsc1LKO mice an HFD for 8 weeks to test
whether they are susceptible to elevations in gluconeogenesis,
but they were found to be protected (Table S1). Given the role
of autophagy in supporting gluconeogenesis during fasting, we
explored whether fasting autophagy was impaired in Tsc1LKO
liver by measuring the liver:body-weight ratio during fasting.
Liver size decreased by 10% after 16 hr and nearly 50% after
24 hr of fasting in control mice. In contrast, Tsc1LKO liver size510 Cell Reports 16, 508–519, July 12, 2016did not decrease after 16 hr and decreased only 30% after
24 hr (Figure 2G), similar to a previous report (Sengupta et al.,
2010).
Tsc1 and Insrb Deletion Impair Hepatic Glycogen
Metabolism
Since glycogen metabolism is regulated by insulin signaling, we
examined whether loss of insulin action or gain of mTORC1 func-
tion altered the ability of the liver to store or utilize glycogen
(Figure 3). Glycogen content was reduced in fed InsrLKO liver (Fig-
ure 3A), as expected, but was also reduced in Tsc1LKOmice (Fig-
ure 3B). In vivo glycogenolysis measured by 2H incorporation
into plasma glucose (Tables S1, S2, and S3) was normal in
InsrLKO mice (Figure 3C) but was reduced by 50% in Tsc1LKO
mice (Figure 3D) on a chow diet relative to liver protein. An
HFD for 8 weeks increased the effect in Tsc1LKO mice so
that whole body glucose production via glycogenolysis was
decreased, even despite larger liver mass (Table S1). We
confirmed reduced glycogen breakdown in HFD Tsc1LKO mice
by measuring liver glycogen content over 16 hr of fasting
(Figure 3E).
To further examine the mechanism of altered glycogen meta-
bolism, mice were fed a high sucrose diet (HSD) to promote
glycogen synthesis and were studied in the fasted and refed
states. The normal rise in plasma glucose following refeeding
was exacerbated in InsrLKO (Figure 3F) but not in Tsc1LKO mice
(Figure 3G). Both InsrLKO and Tsc1LKO mice had reduced
glycogen deposition after refeeding (Figures 3H and 3I). Western
blot analysis indicated that Akt phosphorylation (pAktS473)
and mTORC1 activation assessed by S6 phosphorylation
(pS6S240/244) were induced by refeeding in control mice (Fig-
ure 3J), but deletion of Tsc1 or Insrb blunted this response.
Upon refeeding of InsrLKO mice, Gck (glucokinase) mRNA re-
mained low, while Gys2 (liver isoform of glycogen synthase)
Figure 3. Glycogen Metabolism Is Altered in Livers with Short-Term Inactivation of the Insulin Receptor or mTORC1 Activation
(A–E) Mice on a chow diet (n = 4–7) were fed ad libitum or overnight (17 hr) fasted.
(A and B) Liver glycogen content in InsrLKO (A) and Tsc1LKO (B) mice.
(C and D) In vivo glycogenolysis in InsrLKO (C) and Tsc1LKO (D) mice was measured by 2H incorporation into plasma glucose H2 and H5.
(E) Glycogen depletion was measured in Tsc1LKO mice over a 16-hr fast.
(F–I) Animals fed a high sucrose diet (HSD) for 10 days were examined (n = 5–9) after an overnight fast (17 hr) or refeeding (4 hr) for plasma glucose (F and G) and
liver glycogen (H and I).
(J) Western blot analysis in liver lysates from a subset of animals.
(K and L) mRNA levels of genes related to glycogen metabolism quantified by qRT-PCR.
Data are expressed as the mean and SE, with significant differences determined by unpaired two-tailed Student’s t test assuming equal variances and identified
as *p < 0.05.mRNA was upregulated in InsrLKO livers (Figure 3K). The effects
on gene expression were more modest in Tsc1LKO mice; Gck
was low in the fasted state but was not significantly lower in
the fed state (Figure 3L). Nevertheless, glucokinase and
glycogen synthase proteins were low in Tsc1LKO livers (Fig-
ure 3J). Glycogen synthase kinase (Gsk3a/b) protein phosphor-ylation responded normally to refeeding, but total protein
content was remarkably elevated in Tsc1LKO livers. Consistent
with low Gck mRNA expression in InsrLKO, glucokinase protein
levels were dramatically reduced (Figure 3J), without a change
in the level of glucokinase regulatory protein (data not shown).
Liver glycogen synthase protein in refed InsrLKO mice remainedCell Reports 16, 508–519, July 12, 2016 511
Figure 4. Hepatic Mitochondrial Fluxes Are
Induced by Loss of Insulin Action but Sup-
pressed by mTORC1 Activation
Mice on a chow diet (n = 4–7) were fed ad libitum or
overnight (17 hr) fasted.
(A and B) Plasma ketones in InsrLKO (A) and
Tsc1LKO (B) mice.
(C and D) Apparent ketogenesis measured by




(E–H) Anaplerosis measured in InsrLKO (E) and
Tsc1LKO (F) mice and TCA cycle flux in InsrLKO (G)
and Tsc1LKO (H) mice measured by 13C and 2H
nuclear magnetic resonance (NMR) isotopomer
analysis of plasma glucose.
Data are expressed as the mean and SE, with
significant differences determined by unpaired
two-tailed Student’s t test assuming equal vari-
ances and identified as *p < 0.05.phosphorylated (inactive) following refeeding (Figure 3J).
Gsk3a/b phosphorylation responded normally to refeeding in
InsrLKO mice, but in contrast to Tsc1LKO livers, total protein
was very low, suggesting that glycogen synthase phosphoryla-
tion may be instigated by some other mechanism(s). Thus, insu-
lin receptor loss of function and over-activation of mTORC1
reduce hepatic glycogen synthesis through distinct mecha-
nisms. Changes in mRNA, protein, and phosphorylation levels
in InsrLKO liver are consistent with impaired glycogen synthesis
due to inactivation of glycogen synthase and low glucokinase
content, but reduced glycogen stores in Tsc1LKO livers may be
related to dramatically reduced Gs protein content.
Tsc1 and Insrb Deletion Have Opposite Effects on
Mitochondrial Metabolism
Insulin resistance impinges on oxidative metabolism and mito-
chondrial function; therefore, we examined in vivo fluxes
through mitochondrial pathways (Figure 4). Ketogenesis occurs
predominantly in liver mitochondria by the b-oxidation of fatty
acids and is induced by fasting. Plasma ketones were elevated
in chow-fed InsrLKO mice (Figure 4A) but reduced during fasting
in Tsc1LKO mice (Figure 4B). Likewise, when 13C-labeled ke-
tones were infused into conscious unrestrained mice, the
apparent turnover of acetoacetate and b-hydroxybutyrate
were increased in InsrLKO mice (Figure 4C) but decreased in
Tsc1LKO mice (Figure 4D). This finding was not dependent on
normalization to liver protein (Tables S1 and S2). To examine
in vivo mitochondrial metabolism, 13C tracers of the hepatic
TCA cycle were also infused, and isotopomer analysis of
glucose was performed (Tables S5 and S6). Consistent with
changes in gluconeogenesis, anaplerosis, or the nonoxidative
flux of carbon into the TCA cycle (e.g., pyruvate carboxylation,
glutaminolysis, etc.), was increased by 50% in fed InsrLKO
mice (Figure 4E) and decreased by 35% in fed Tsc1LKO mice512 Cell Reports 16, 508–519, July 12, 2016on a chow diet (Figure 4F). Oxidative
metabolism in the TCA cycle was gener-
ally decreased by fasting (Figures 4Gand 4H), consistent with a recent study using similar methodol-
ogy (Hasenour et al., 2015). InsrLKO mice had an overall increase
in hepatic TCA cycle flux but remained responsive to the nutri-
tional state (Figure 4G). In contrast, hepatic TCA cycle flux in
Tsc1LKO mice was reduced and unresponsive to the nutritional
state (Figure 4H).
We examined several factors that might contribute to lower
oxidative metabolism in the liver of HFD Tsc1LKOmice (Figure 5).
Neither NEFAs (nonesterified fatty acids) (Figure 5A) nor mito-
chondrial content evaluated by homogenate citrate synthase
(Cs) activity relative to liver mass were reduced in Tsc1LKO
mice (Figure 5B). However, expression of several hepatic genes
that regulate fat oxidation, including Ppara, Cpt1, and Hmgcs2,
were lower in in Tsc1LKO livers (Figure 5C). In contrast, Acacb
mRNA was increased 2-fold, and Mcd mRNA was decreased
2-fold (Figure 5C). These two enzymes catalyze the synthesis
and degradation of malonyl-coenzyme A (CoA), an inhibitor of
Cpt1-mediated lipid transport into the mitochondria. Total Acc
protein, but not phosphorylation, tended to be increased (Fig-
ures 5D–5E). In addition, when refed mice were treated with
rapamycin to inhibit mTORC1, Acc phosphorylation was robustly
increased (Figure 5F), confirming that mTORC1 impinges
directly or indirectly on Acc. Although malonyl-CoA concentra-
tion was not increased (Figure 5G), malonylcarnitine (C3DC/
C5OH, includes 3-hydroxy-isovalerylcarnitine) was significantly,
though modestly, elevated in the liver of fasted Tsc1LKO mice
(Figure 5H). To directly test whether b-oxidation is impaired,
Tsc1LKO liver homogenates from fasted HFD animals were
exposed to [1-14C]palmitate and found to have a clear reduction
in 14C metabolites (Figure 5I), consistent with reduced in vivo
ketogenesis (Figure 4D) and an overall reduction in b-oxidation.
Thus, mTORC1 activation appears to suppress fat oxidation
in vitro and in vivo by reducing the expression of oxidative genes
and, possibly, by inhibiting Acc phosphorylation.
Figure 5. Activation of mTORC1 in Tsc1LKO Mice Suppresses Mechanisms of Fat Oxidation
(A–I) Mice on an HFD for 8 weeks (n = 4–7) were fed ad libitum or overnight (17 hr) fasted.
(A) Plasma NEFAs.
(B) Mitochondrial content assessed by CS activity in tissue homogenate.
(C) qRT-PCR analysis of genes related to fat oxidation.
(D) Western blot analysis in liver lysates from a subset of animals.
(E) Quantification of Acc and pAcc.
(F) Stimulation of Acc phosphorylation by rapamycin-induced mTORC1 inhibition.
(G) In vitro [1-14C]palmitate oxidation.
(H and I) Hepatic malonyl-CoA (H) and malonylcarnitine (I).
Data are expressed as the mean and SE, with significant differences determined by unpaired two-tailed Student’s t test assuming equal variances and identified
as *p < 0.05.Simultaneous Loss of Insulin Action and Activation of
mTORC1 Recapitulate Some Metabolic Features of
Insulin Resistance
Moderate-duration (6–8 weeks) HFD models have relatively few
overt metabolic disturbances but eventually develop hypergly-
cemia, defects in glycogen metabolism, impaired b-oxidation,
and ketogenesis, with more severe obesity and insulin resis-
tance. Since continued activation of mTORC1 during insulin
resistance may play a role in altered hepatic metabolism (Li
et al., 2010), we examined InsrLKO,Tsc1LKO (Insr/Tsc1DLKO)
mice on an HFD for 8 weeks to determine whether stimulation
of mTORC1 in the setting of impaired insulin action recapitulatessevere diet-induced insulin resistance (Figure 6). Insr/Tsc1DLKO
mice had body weights similar to those of InsrLKO/Tsc1+/+ and
Insr+/+/Tsc1LKO mice. Loss of Tsc1 at least partially rescued
the smaller liver size associated with loss of Insrb (Figure 6A),
indicating that activation of mTORC1 is sufficient to stimulate
growth. Insulin levels were not reduced in Insr/Tsc1DLKO mice
compared to InsrLKO/Tsc1+/+ mice (Figure 6B). Liver triglyceride
concentration was reduced in Insr+/+/Tsc1LKO, as previously re-
ported (Kenerson et al., 2015), and was also reduced in Insr/
Tsc1DLKO mice compared to InsrLKO/Tsc1+/+, indicating that the
reduction in liver triglycerides was independent of insulin action
(Figure 6C). To evaluate hepatic fat oxidation, we examinedCell Reports 16, 508–519, July 12, 2016 513
Figure 6. Simultaneous Loss of Insulin Action and Activation of
mTORC1 Reduced Ketogenesis, Provoked Hyperglycemia, and
Severely Impaired Glycogen Storage
Double Insr/Tsc1 LKO mice were made by crossing Tsc1f/+ and Insrf/f mice.
Mice were fed an HFD for 8 weeks and treated with Ad-Cre 2 weeks prior to
sample collection. The () designates that the gene was floxed or (+) not
floxed. Mice were fed ad libitum or overnight fasted (n = 6–9).
(A) Percent liver weight compared to body weight (BW).
(B) Plasma insulin.
(C) Liver triglyceride content.
(D) Plasma total ketone concentration.
(E) Plasma glucose.
(F) Liver glycogen content.
Data are expressed as the mean and SE, with significant differences deter-
mined by unpaired two-tailed Student’s t test assuming equal variances and
identified as *p < 0.05.fasting plasma ketone concentration. In agreement with reduced
ketogenesis caused by activation of mTORC1 (Table S1), both
Insr+/+/Tsc1LKO mice and Insr/Tsc1DLKO mice had low ketone
concentration (Figure 6D). In contrast to the effects on ketogen-
esis, fed glucose in Insr/Tsc1DLKO mice was elevated compared514 Cell Reports 16, 508–519, July 12, 2016to InsrLKO/Tsc1+/+ (Figure 6E). Although gluconeogenesis was
not measured in Insr/Tsc1DLKO mice, absolute endogenous
gluconeogenesis (not normalized to liver protein) was not
elevated in fasted or fed Tsc1LKO or InsrLKO mice (Tables S1
and S2). In contrast, liver glycogen storage in fed mice was
impaired in InsrLKO/Tsc1+/+ mice and further impaired in Insr/
Tsc1DLKO mice (Figure 6F). These data are consistent with
distinct mechanisms of impaired glycogen metabolism caused
by loss of insulin action and gain of mTORC1 function and sug-
gest that impaired glycogen storage is involved in the aggrava-
tion of hyperglycemia in the Insr/Tsc1DLKO mice.
An HFD for 8 Weeks Activates mTORC1 and Suppresses
TCA Cycle Flux in Liver of Fed Mice
We previously reported that 16 weeks, but not 8 weeks, of an
HFD caused elevated fasting hepatic TCA cycle flux (Satapati
et al., 2012), partially due to elevated anaplerosis and gluconeo-
genesis (Satapati et al., 2015). Since mTORC1 is nutritionally
regulated, we examined whether its role in meditating dysregu-
latedmetabolism during anHFD is dependent on nutritional state
(Figure 7). An HFD for 16 weeks was sufficient to cause
increased mTORC1 activity, as indicated by elevated pS6/S6,
particularly in the fed state (Figure 7A). As in our previous study
(Satapati et al., 2012), 8 weeks of an HFD had no effect on oxida-
tive fluxes in fasted mice. However, flux through the TCA cycle
was significantly diminished in the fed state of mice on an HFD
(Figure 7B). Activation of mTORC1 in chow-fed Tsc1LKO mice
caused a similar reduction of TCA cycle flux, which was not
further decreased by an HFD (Figure 7B). In contrast, 8 weeks
of an HFD had no effect on ketogenesis in control mice (Fig-
ure 7C), similar to our previous report (Sunny et al., 2010), but
caused a reduction in ketogenesis when mTORC1 was constitu-
tively active (Figure 7C). Thus, 8 weeks of an HFD or activation of
mTORC1 similarly suppressed TCA cycle oxidative flux in the fed
mice and together potentiated impaired b-oxidation in the fasted
state.
DISCUSSION
The complex signaling network of mTor kinase integrates a
plethora of positive and negative regulatory events for cell
growth, replication, survival, aging, and metabolism (Laplante
and Sabatini, 2013). mTORC1 is an important downstream
node of the insulin signaling pathway and, hence, is expected
to govern certain features of insulin action. These features are
presumed to be dominated by anabolic pathways like growth,
protein synthesis, and lipid synthesis. However, mTORC1 also
participates in the pathophysiology of insulin resistance. Hepatic
mTORC1 is over-activated in obese rodents (Figure 7A) (Kham-
zina et al., 2005) and may induce a negative-feedback loop from
S6K1 to IRS1 (Harrington et al., 2004) and worsen insulin
signaling. Constitutive activation of mTORC1 during hyperinsuli-
nemia may also mediate the paradoxical activation of lipid
synthesis through downstream targets that activate Srebp (Li
et al., 2010). However, long-term mTor inhibition with rapamycin
also induces a metabolic syndrome, including insulin resistance,
glucose intolerance, and dyslipidemia (Laplante and Sabatini,
2012). In mice, 2 weeks of rapamycin treatment decreases
expression of insulin signaling proteins in muscle (Bla¨ttler et al.,
Figure 7. An HFD Activates mTORC1 and Suppresses TCA Cycle Flux in Liver of Fed Mice
(A) Western blot and quantification of S6 phosphorylation and total S6 as indicated by mTORC1 activation during an HFD.
(B and C) TCA cycle flux in fed (B) and ketogenesis in fasted (C) Tsc1+/+ and Tsc1LKO on either chow or an HFD (n = 4–7).
(D) Effects of loss of insulin action, mTORC1 activation, and/or HFD on mitochondrial metabolism.
Data are expressed as the mean and SE, with significant differences determined by unpaired two-tailed Student’s t test assuming equal variances and identified
as *p < 0.05.2012) and inhibits assembly of both mTORC1 and mTORC2 in
various tissues, with the latter playing an important role in hyper-
insulinemia, systemic insulin resistance, and glucose intolerance
(Lamming et al., 2012). Nevertheless, very long (20-week) rapa-
mycin treatment (Fang et al., 2013) or genetic inactivation of
mTORC1 activity improves insulin sensitivity and hyperglycemia
in mice (Vo¨lkers et al., 2014). Thus, while well studied, the inter-
action of mTORC1 with the metabolic actions of insulin is com-
plex; varies between acute and chronic action; and is, overall,
still poorly understood.
Although an HFD impairs hepatic insulin action, it also acti-
vatesmTORC1, yet conditional loss of insulin signaling or activa-
tion of mTORC1 had opposite effects on liver metabolism.
mTORC1 activation by hepatic Tsc1 ablation for up to 8 weeks
does not increase plasma glucose concentration in mice (Kener-
son et al., 2011; Sengupta et al., 2010). Tsc1LKO animals
repressed G6pase normally (and Pck1 partially) in response to
refeeding and had reduced fasting gluconeogenic flux on an
HFD but not on a chow diet. Loss of the insulin receptor for
2 weeks caused the failed repression of hepatic G6pase and
Pck1 and very low Gck upon refeeding, an effect that is similar
to that in fed LIRKO mice (Michael et al., 2000), but endogenous
glucose production was not increased. Thus, InsrLKO mice ex-
hibited a phenotype similar to that of young LIRKO animals,
which were reported to have hyperinsulinemia but normoglyce-
mia for up to 4 weeks of age (Okada et al., 2007).
Activation of mTORC1 can suppress gluconeogenesis via at
least two potential mechanisms. Phosphorylation and activation
of S6k by mTORC1 induces the phosphorylation of Pgc1 at sites
that render it unable to activate gluconeogenic genes via HNF4a
but preserve its ability to maintain mitochondrial biogenesis
(Lustig et al., 2011). Indeed, gluconeogenic genes were reduced
in Tsc1LKO liver. In addition, reduced gluconeogenesis in
newborn mice with activation of mTORC1 was previously attrib-
uted to inhibition of autophagy and restricted supply of amino
acids for gluconeogenesis (Efeyan et al., 2013). Amino acid
levels trended lower in 24-hr-fasted Tsc1LKO animals on an
HFD (data not shown), and loss of liver mass during fasting
was substantially delayed. In agreement with the establishedrole of insulin action and mTORC1 in tissue growth, Tsc1LKO
mice had increased total liver protein, while InsrLKO mice had
decreased total liver protein. Liver mass was also an important
factor influencing metabolic flux in a practical sense. Total
absolute flux (mmol , min1) was only modestly altered in
some instances in either Tsc1LKO or InsrLKO mice. However,
since liver mass was markedly increased by mTORC1 activation
and decreased by insulin receptor loss, striking effects were
observed in functional hepatocellular fluxes (mmol , min1 , g
liver protein1).
Despite having opposite effects on gluconeogenesis, both
loss of the insulin receptor and activation of mTORC1 reduced
rates of glycogenolysis and glycogen synthesis. The role of insu-
lin action on hepatic glycogenolysis is expected (Buettner et al.,
2005), but the role ofmTORC1 in hepatic glycogenmetabolism is
less appreciated. However, several mechanisms link mTORC1
activation to impaired glycogen metabolism. First, blunted Akt
phosphorylation may contribute to low hepatic glycogen in
both Tsc1LKO and InsrLKO mice via Gsk3-dependent and -inde-
pendent mechanisms (Wan et al., 2013). Indeed, this appears
to be the case in InsrLKOmice, which had low total and phosphor-
ylated Gsk3 and failed to dephosphorylate glycogen synthase
(Gs) after refeeding. This mechanism appears less important
in Tsc1LKO mice, which maintained Gsk3 regulation. Second,
mTORC1 was recently reported to activate glycogen synthe-
sis through Srebp-mediated regulation of protein-targeting
glycogen (PTG) (Lu et al., 2014). Indeed, mTORC1 activation
paradoxically reduced Srebp-1c mRNA by more than 2-fold
(data not shown). Finally, the most prominent defect related to
glycogen in Tsc1LKO mice was not Gs phosphorylation but,
rather, a substantial reduction in Gs protein content. Indeed,
glycogenmetabolism is additive in the Insrb/Tsc1DLKO, consis-
tent with independent mechanisms by which Tsc1LKO and
InsrLKO perturb glycogen metabolism.
Like hepatic glucosemetabolism, hepaticmitochondrial meta-
bolism is also nutritionally responsive and partially regulated
through insulin signaling mechanisms. Fasting caused a sup-
pression of TCA cycle flux, similar to findings of a recent study
(Hasenour et al., 2015). We tested whether loss of insulin actionCell Reports 16, 508–519, July 12, 2016 515
and/or constitutive activation of mTORC1 are individually suffi-
cient to modulate mitochondrial oxidative metabolism. The
loss of insulin receptor increased in vivo hepatic oxidative meta-
bolism, evident as elevated oxidative TCA cycle flux in fed mice
and elevated ketogenesis in fasted mice. The activation of
mTORC1 had a strikingly opposite effect by suppressing TCA
cycle oxidative flux in the fed state and ketogenic flux in the
fasted state. The suppression of hepatic ketogenesis by activa-
tion of mTORC1 is thought to involve repression of Ppara
through the activation of nuclear receptor co-repressor 1 and
downregulation of Hmgcs2 (Sengupta et al., 2010), a critical
enzyme in ketogenesis. Indeed, we found that mTORC1 activa-
tion induced Ppara oxidative target genes, including Hmgcs2. In
addition, Acc2 mRNA and protein content were increased, but
Mcd was reduced, which may induce malonyl-CoA levels in
the vicinity of mitochondria and suppress Cpt1-mediated fat
transport into mitochondria (McGarry, 2002). It is interesting
that fasting reduces TCA cycle flux but loss of insulin action
(a fasting-like state) increases and that mTORC1 activation
(a fed-like state) suppresses TCA cycle flux. Perhaps it is
most notable that constitutive activation of mTORC1 ablated
the nutritional responsiveness of hepatic energy metabolism,
as observed by the blunted TCA cycle flux in fed mice and no
further reduction by fasting. On the other hand, the loss of the
insulin receptor elevated oxidative fluxes regardless of nutri-
tional state, but the decrement due to fasting was retained.
Thus, mTORC1 deactivation, but not necessarily insulin action
per se, is required for nutritional flexibility of oxidative meta-
bolism in liver.
Since insulin resistance activates mTORC1, an HFD should
recapitulate aspects of the Tsc1LKO and InsrLKO mice. Observa-
tions in humans and animal models indicate a spectrum of
changes in hepatic mitochondrial metabolism during insulin
resistance. Mild insulin resistance may have no effect, while
moderate insulin resistance induces hepatic oxidative meta-
bolism, andmore severe insulin resistance is associated with de-
fects in b-oxidation and respiration (Cheng et al., 2009; Koliaki
et al., 2015; Rector et al., 2010; Satapati et al., 2008, 2012; Sunny
et al., 2011). However, an important finding reported here is that
the nutritional state of the subject may be as important as the de-
gree of obesity/insulin resistance when it comes to understand-
ing the effect on mitochondrial metabolism. For example, an
HFD for 16 weeks caused increased oxidative flux in liver of
fasted mice, but 8 weeks seemed to have no effect (Satapati
et al., 2012). This increase could be explained by elevated ana-
plerosis and gluconeogenic energy demand (Satapati et al.,
2015), and since 8 weeks of an HFD was not sufficient to alter
these fluxes in the fasted state, an effect on mitochondrial meta-
bolism was not observed. However, even short durations of an
HFD are sufficient to cause hepatic insulin resistance, so effects
on mitochondrial metabolism might be best observed in mice
that are not fasted, when insulin resistance is most prominent.
Indeed, the increment between fed and fasted states was
essentially abolished after 8 weeks of an HFD. Thus, in fed
mice, our results are similar to those of Thyfault and colleagues,
who found impaired hepatic oxidative capacity in rat models
susceptible to hepatic steatosis (Thyfault et al., 2009). Hence,
it appears that an HFD in mice induces oxidative metabolism in516 Cell Reports 16, 508–519, July 12, 2016the fasted state but suppresses it in the immediate post-absorp-
tive state and, perhaps, overall reduces the nutritional flexibility
of the pathway.
This ‘‘flexibility’’ in oxidative metabolism may be governed in
part by mTORC1 activation. Activation of mTORC1 for 2 weeks
closely resembles the effect of 8 weeks of an HFD, by suppress-
ing the oxidative TCA cycle in fed mice, and resembles more
severely insulin-resistant models by suppressing fasting keto-
genesis. Thus, reduced oxidative mitochondrial function could
precede frank insulin resistance, as previously described (Rector
et al., 2010), through mTORC1 or other discrete signaling path-
ways activated by obesity. Severely insulin-resistant models,
such as leptin-receptor-deficient rats, have a strong induction
of mTor signaling (Zheng et al., 2009) and reduced hepatic
fat oxidation secondary to impaired ketogenesis (Satapati
et al., 2008). A similar but less severe effect is observed after
a long-term (32-week) HFD (Satapati et al., 2012). The suppres-
sion of ketogenesis by mTORC1 activation may have important
implications for fatty liver disease, which was recently demon-
strated to progress from steatosis to steatohepatitis when keto-
genesis was suppressed by Hmgcs2 loss (Cotter et al., 2014).
Thus, it is significant that, in the setting of lost insulin action,
mTORC1 activation was sufficient to suppress ketogenesis
and potentiate hyperglycemia, partially mediated by impaired
glycogen storage.
Although we interpret the data to indicate that insulin
signaling and mTORC1 activation can partially mediate the
hepatic metabolic effects of diet-induced obesity, the study
has several limitations. The background strains of the LKO
mice were not perfectly controlled. InsrLKO mice were pur-
chased backcrossed, and C57bl/6J control mice were used
as suggested by Jackson Laboratory (Jackson Laboratory,
2016). However, subsequent information suggests that the
mice are actually C57bl/6N (Jackson Laboratory, 2016). Thus,
comparison between InsrLKO and Tsc1LKO mice could not be
made. Since DLKO mice were created by crossing heterozy-
gous mice, those comparisons should be valid, though flux
was not measured in that cohort. We also noted that, following
the Ad-Cre injections 2 weeks prior to studies, mice stopped
gaining weight on an HFD; thus, the weight of the mice was
slightly less than usual for mice on an 8-week HFD, though
they were still significantly heavier than chow-fed mice. Com-
parisons to control mice should be valid, since they were also
administered Ad-Cre.
Finally, it has been suggested that propionate tracers of TCA
cycle metabolism alter flux and yield substantially different
values compared to lactate tracers (Perry et al., 2016). However,
we recently validated our approach by correlating tracer flux and
oxygen consumption in perfused liver, by measuring in vivo
glucose production with/without propionate, and by direct com-
parison of propionate and lactate tracers (Satapati et al., 2015).
Neither an independent group (Hasenour et al., 2015) nor we (Sa-
tapati et al., 2015) could identify substantial effects of propionate
on TCA cycle flux when used at tracer levels and analyzed by an
appropriate mathematical model. In fact, lactate tracers have
historically reported relative fluxes similar to ours (Beylot et al.,
1995; Landau et al., 1995), so we are uncertain why another
group obtained very different results with lactate and other
tracers (Befroy et al., 2014; Perry et al., 2016). For the interested
reader, we recommend a recent review (Previs and Kelley, 2015).
In summary, loss of insulin action and constitutive activation of
mTORC1 both occur during hepatic insulin resistance. Short-
term inactivation of hepatic Tsc1 constitutively activated
mTORC1 and opposed many of the metabolic effects observed
in InsrLKO mice, with the exception of glycogen metabolism,
which was suppressed by both. An 8-week HFD caused the sup-
pression of hepatic TCA cycle flux in the fed, but not fasted,
state, and this was recapitulated in chow-fed Tsc1LKO mice.
The loss of insulin action, rather than mTORC1 activation, ap-
pears to be more directly related to the upregulation of fluxes
of the TCA cycle, as observed in fasted mice after 16 weeks of
an HFD. Together, insulin resistance and mTORC1 activation
may account for a loss in the responsiveness of mitochondrial
fluxes to nutritional state during obesity and insulin resistance.
EXPERIMENTAL PROCEDURES
Animals
All animal experiments were approved by The University of Texas South-
westernMedical Center Institutional Animal Care andUseCommittee (IACUC).
Insrbflox/flox (Aasum et al., 2003) mice were purchased from Jackson Labora-
tory, and C57BL/6J control mice were used as suggested (Jackson Labora-
tory, 2016). Tsc1flox/flox (Kwiatkowski et al., 2002) mice on a mixed background
were backcrossed to C57BL/6J for three to eight generations and compared
to littermate Tsc1+/+ control animals. Double-floxed mice were generated first
by crossing Insrbflox/flox with Tsc1flox/+ mice from the third generation of back-
cross, and Insrbflox/+ Tsc1flox/+ offspring were then crossed with Insrbflox/flox
mice to obtain Insrbflox/flox Tsc1flox/+ mice. These mice were used as parents
for the experimental Insrbflox/flox Tsc1+/+ and Insrbflox/flox Tsc1flox/flox animals.
Male mice were 14–16 weeks old at the time of the sacrifice, maintained on
12-hr/12-hr dark/light cycle, with unrestricted access to food and water unless
otherwise noted. Animals were fed standard chow (NCD; Teklad Diet 2016,
Harlan Laboratories), an HFD (60% fat calories, Teklad Diet TD06414; Harlan
Laboratories) for 8 weeks, or an HSD (10% fat calories, 70% sucrose calories,
diet D07042201, Research Diets) for 10 days.
Ad-Cre (Gene Transfer Vector Core, University of Iowa) was expanded in
HEK293T cells and purified using the Adeno-XMaxi Purification Kit (Clontech).
Elution media was exchanged for 0.9% saline using a PD10 desalting column
(GE Healthcare), and 1.3–1.5 3 109 plaque-forming units (PFUs) of virus per
animal was injected into the tail vein of control and floxed mice 14 days before
sacrifice.
Stable Isotope Tracer Infusions
Infusions were performed as described previously (Satapati et al., 2012).
Briefly, on day 4 after surgical implantation of indwelling jugular vein catheters,
mice that were either fed ad libitum or overnight (17 hr) fasted were placed in a
clean cage. Unrestrained mice were infused with [3,4-13C2]acetoacetate and
[U-13C4]sodium b-hydroxybutyrate as a bolus (8.8 and 6.7 mmol/hr, respec-
tively) for 10 min, followed by 80 min of continuous infusion (3.5 and
2.7 mmol/hr, respectively). At the end of the infusion, 50 ml of blood was
collected for liquid chromatography-tandem mass spectrometry (LC-MS/
MS) analysis of ketone turnover (Sunny et al., 2010). Mice then received an
intraperitoneal injection of isotonic D2O (99%; 27 ml per body weight).
[U-13C3]propionate and [3,4-
13C2]glucose were infused as a bolus (0.15 and
6 mmol/hr, respectively) over 10 min, followed by 80 min of continuous infusion
(0.03 and 1.2 mmol/hr, respectively). After infusions,mice were anesthetized by
isoflurane (Aerrane, Baxter), and blood was collected until exsanguinated by
cardiac puncture. Liver was collected and flash-frozen in liquid nitrogen. Sam-
ples were stored at 80C until further analysis. Altogether, fed mice were
without food for 4 hr, and fasted mice were without food for 21 hr. Fluxes
were evaluated as previously described (Satapati et al., 2012) and elaborated
upon in the Supplemental Information.Oxidation of Palmitate in Liver Homogenates
In vitro oxidation of palmitate was performed as described by Dohm et al.
(1972), with few modifications. Briefly, overnight (16-hr)-fasted animals were
anesthetized by isoflourane, and blood was collected by cardiac puncture.
Liver was excised and submerged into ice-cold reaction buffer (2 mM ATP,
0.05 mM CoA, 1 mM dithiothreitol, 0.1 mM NAD+, 1 mM DL-carnitine,
0.1 mMmalate, 1 mMMgCl2, 0.072 mM fatty-acid-free BSA, 100mM sucrose,
10 mM K2HPO4, 80 mM KCl, 0.1 mM EDTA, 100 mM HEPES [pH 7.3]).
500 mg of liver was homogenized in 2.5 ml of reaction buffer by 11 strokes
of hand-operated Potter-Elvehjem homogenizer. Reaction was started by
adding 3 ml of [1-14C]palmitate (0.3 mCi; final 25 mM; PerkinElmer) to 200 ml of
homogenate. The tube was immediately inserted into a vial with silicone septa
containing filter paper soaked in hyamine hydroxide to capture 14CO2. Reac-
tions were incubated at 37C for 4, 5, 6, and 7 min (duplicate for each time
point) and terminated by injecting 100 ml of 7% (v/v) HClO4. To ensure
complete capture of 14CO2, vials were left at 4
C overnight. On the next day,
the reaction tube was centrifuged at 15,000 3 g for 10 min. 200 ml of
supernatant, as well as filter paper, was counted for incorporation of 14C
into acid-soluble molecules and 14CO2 in 6 ml of scintillation liquid. After
conversion to DPM and correction for scintillation counter efficiency, the
oxidation rate was calculated as picomoles of oxidized palmitate per minute
per milligram of tissue.
Blood and Tissue Analysis
Blood glucose was measured by glucometer (Accuchek, Roche Diagnostics).
Analytical kits were used to determine liver and serum triglycerides (Sigma-
Aldrich), plasma free fatty acids (Wako Chemicals), and total ketones (Wako
Chemicals). Plasma insulin was measured using an ELISA kit (Crystal Chem).
Liver triglycerides were isolated by Folch extraction. Liver glycogen was iso-
lated from tissue homogenized in 30% (w/v) KOH (1 ml/100 mg of tissue) and
hydrolyzed in a boiling water bath for 15 min. Samples were centrifuged at
3,000 3 g for 5 min, and 150 ml of supernatant was spotted onto a Whatman
paper disc. The disc was washed twice with ice-cold 70% (v/v) ethanol, dried,
submerged into 2 ml of 0.2 mg/ml amyloglucosidase in 50 mM sodium acetate
(pH 4.8), and incubated at 55C for 1 hr. 30–50 ml of reaction were used to
determine glucose concentration.
Real-Time qRT-PCR
RNA was isolated using RNA Stat 60 (Tel-Test). cDNA was synthesized using
2 mg of total RNA and iScript Advanced cDNA Synthesis Kit (BioRad). PCRwas
run using iTaq Universal SYBR Green Supermix (BioRad) and the CFX384
Touch Real-Time PCR Detection System (BioRad).
Western Blot Analysis
Tissue was homogenized in RIPA buffer (Cell Signaling) with cOmplete prote-
ase inhibitors (Roche) followed by two 10-s sonications at 10% amplitude
(Branson). Lysates were centrifuged at 21,000 3 g for 5 min, and supernatant
without fat layer was used in western blotting. Signals were detected using
SuperSignal Pico chemiluminiscent substrate (Pierce, Thermo Fisher) and
the ImageQuant LAS 4000 system (GE Healthcare). Antibodies were obtained
from the following sources: Cell Signaling: Acc, pAcc(S79), Akt, pAkt(S473),
Gs, pGs(S641), Gsk3, pGsk3(S21/9), Insrb, S6, pS6(S240/244), Tsc1; Santa
Cruz: Gck; Abcam: Ppib.
Chemicals
Stable isotope compounds were obtained from the following sources: Omi-
cron Biochemicals: [3,4-13C2] glucose (98%); Isotec: [3,4-
13C2]ethylacetoace-
tate and [U-13C4]sodium b-hydroxybutyrate (98%); Cambridge Isotopes:
[U-13C3]propionate and [U-
13C3]glucose. Other common chemicals were ob-
tained from Sigma.
Statistical Analysis
All data are presented as means ± SE. Statistical analysis and graph prepara-
tion were performed in Prism 6 (GraphPad Software). Outliers were identified
using a Grubb’s test. The p values were calculated by unpaired two-tailed Stu-
dent’s t test, assuming equal variances. Statistically significant difference is
marked as *p < 0.05.Cell Reports 16, 508–519, July 12, 2016 517
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